US03843E1047
US03843E1047
Aquestive Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 50/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±82.2% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 1.5x as much as the broader market.
Beta (Market Relation)
1.49x
Above averageVolatility (5Y p.a.)
82.2% p.a.
5-Year HorizonMax Drawdown (5Y)
-90.1%
5-Year HorizonSharpe Ratio
0.03
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -23.2% |
| 3 Years | 79.5% | -63.5% | 0.64 | +53.3% |
| 5 Years | 82.2% | -90.1% | 0.03 | +5.2% |
| 10 Years | 86.5% | -96.7% | -0.19 | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (82.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -96.7% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
7 ISS Score: 7 / 10
Audit Risk
9 ISS Score: 9 / 10
Board Risk
6 ISS Score: 6 / 10
Short Ratio
9.05